These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12921040)

  • 1. Niacin aids cholesterol control. But choose "extended release" to minimize "flushing" risk.
    Heart Advis; 2003 Jul; 6(7):3. PubMed ID: 12921040
    [No Abstract]   [Full Text] [Related]  

  • 2. Avoid no-flush niacin in favor of the prescription version. Follow certain steps to reduce the flushing effects of prescription niacin.
    Heart Advis; 2010 Nov; 13(11):5. PubMed ID: 22834056
    [No Abstract]   [Full Text] [Related]  

  • 3. Niacin: its value in raising HDL cholesterol is being questioned.
    Heart Advis; 2011 Oct; 14(10):7. PubMed ID: 23019714
    [No Abstract]   [Full Text] [Related]  

  • 4. Niacin into the void. Failure of HDL cholesterol drug may B this vitamin's big chance.
    Harv Health Lett; 2007 Apr; 32(6):6. PubMed ID: 17390509
    [No Abstract]   [Full Text] [Related]  

  • 5. More on niacin: no flush, no good.
    Harv Health Lett; 2007 Jul; 32(9):7. PubMed ID: 17663076
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Termination of Atherothrombosis Intervention in Metabolic Syndrome with Low High-Density Lipoprotein Cholesterol and High Triglycerides: Impact on Global Health Study and decision to use extended-release niacin in elderly.
    Shil AB
    J Am Geriatr Soc; 2011 Dec; 59(12):2397-8. PubMed ID: 22188098
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and tolerability of extended-release niacin with laropiprant.
    Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
    Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What is the future for niacin after the AIM-HIGH study?].
    Cybulska B; Kłosiewicz Latoszek L
    Kardiol Pol; 2012; 70(3):315-6. PubMed ID: 22430425
    [No Abstract]   [Full Text] [Related]  

  • 10. New thinking on niacin use. Using niacin to raise "good" cholesterol doesn't lower your risk of having a heart attack or stroke.
    Harv Health Lett; 2014 Aug; 39(10):6. PubMed ID: 25230410
    [No Abstract]   [Full Text] [Related]  

  • 11. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
    Benhalima K; Muls E
    Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial.
    Nash MS; Lewis JE; Dyson-Hudson TA; Szlachcic Y; Yee F; Mendez AJ; Spungen AM; Bauman WA
    Arch Phys Med Rehabil; 2011 Mar; 92(3):399-410. PubMed ID: 21276961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin: the only vitamin that reduces cardiovascular events.
    Wierzbicki AS
    Int J Clin Pract; 2011 Apr; 65(4):379-85. PubMed ID: 21401825
    [No Abstract]   [Full Text] [Related]  

  • 16. Extended-release niacin raises adiponectin and leptin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Atherosclerosis; 2007 Aug; 193(2):361-5. PubMed ID: 16887123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of laropiprant on niacin-induced flushing.
    Maccubbin DL; Chen F; Anderson JW; Sirah W; McCrary Sisk C; Kher U; Olsson AG; Bays HE; Mitchel YB
    Am J Cardiol; 2012 Sep; 110(6):817-22. PubMed ID: 22683042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin plus statin: powerful anti-cholesterol partnership. Use of the B vitamin niacin may help keep your cholesterol under control, but there are certain things you should know before starting therapy.
    Heart Advis; 2007 Jul; 10(7):9. PubMed ID: 17695658
    [No Abstract]   [Full Text] [Related]  

  • 19. A case for immediate-release niacin.
    Bassan M
    Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of flushing due to niacin and abolition of these effects.
    Sood A; Arora R
    J Clin Hypertens (Greenwich); 2009 Nov; 11(11):685-9. PubMed ID: 19878384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.